Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy

Journal of Ocular Pharmacology and Therapeutics

Volumn 23, Issue 1, 2007, Pages 14-20

  Kuo, Hsi Kung ^a,b   Wu, Pei Chang ^a,b,c   Yang, Po Min ^a   Chen, Yi Hao ^a   Wu, Yi Chan ^a   Hu, Dan Ning ^d,e  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e NEW YORK EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; EXPERIMENTAL MODEL; IN VITRO STUDY; LOW DRUG DOSE; NONHUMAN; PIGMENT EPITHELIUM; RABBIT; TOXICITY TESTING; VITREORETINOPATHY;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DAUNORUBICIN; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG TOXICITY; ENZYME INHIBITORS; ETOPOSIDE; INJECTIONS; MALE; MAXIMUM TOLERATED DOSE; PIGMENT EPITHELIUM OF EYE; RABBITS; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 33947411877     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.0059     Document Type: Article

References (25)

1. Chignell, A.H., Fison, L.G., Davies, B.W., et al. Failure in retinal detachment surgery. Br. J. Ophthalmol. 57:525-530, 1973.
2. Pastor, J.C. Proliferative vitreoretinopathy: An overview. Surv. Ophthalmol. 43:3-18, 1998.
3. Clarkson, J.G., Green, W.R., and Massof, D. A histopathologic review of 168 cases of preretinal membrane. Am. J. Ophthalmol. 84:1-17, 1977.
4. Machemer, R., van Horn, D., and Aaberg, T.M. Pigment epithelial proliferation in human retinal detachment with massive periretinal proliferation. Am. J. Ophthalmol. 85:181-191, 1978.
5. Vinores, S.A., Campochiaro, P.A., and Conway, B.P. Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Invest. Ophthalmol. Vis. Sci. 31:14-28, 1990.
6. Morino, I., Hiscott, P., McKechnie, N., et al. Variation in epiretinal membrane components with clinical duration of the proliferative tissue. Br. J. Ophthalmol. 74:393-399, 1990.
7. Glaser, B.M., Vidaurri-Leal, J., Michels, R.G., et al. Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. Ophthalmology 100:466-470, 1993.
8. Salah-Eldin, M., Peyman, G.A., El-Aswad, M., et al. Evaluation of toxicity and efficacy of a combination of antineoplastic agents in the prevention of PVR. Int. Ophthalmol. 18:53-60, 1994.
9. Wiedemann, P., Hilgirs, R.D., Bauer P., et al. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: Results of a multicenter clinical trial. Am. J. Ophthalmol. 126:550-559, 1998.
10. Asaria, R.H., Kon, C.H., Bunce, C., et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial. Ophthalmology 108: 1179-1183, 2001.
11. Yang, C.S., Khawly, J.A., Hainsworth, D.P., et al. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch. Ophthalmol. 116:69-77, 1998.
12. Rubsamen, P.E., and Cousins, S.W. Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy. Retina 17:44-50, 1997.
13. Wu, W.C., Kao, Y.H., and Hu, D.N. A comparative study of effects of antiproliferative drugs on human retinal pigment epithelial cells in vitro. J. Ocul. Pharmacol. Ther. 18:251-264, 2002.
14. Ozerdem, U., Mach-Hofacre, B., Keefe, K., et al. The effect of prinomastat, a synthetic inhibitor of matrix metalloproteinases, on post-traumatic proliferative vitreoretinopathy. Ophthalmic Res. 33:20-23, 2001.
15. Eibl, K.H., Banas, B., Schoenfeld, C.L., et al. Alkylphosphocholines inhibit proliferation of human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 44:3556-3561, 2003.
16. Wu, W.C., Hu, D.N., Mehta, S., et al. Effects of retinoic acid on retinal pigment epithelium from excised membrane from proliferative vitreoretinopathy. J. Ocul. Pharmacol. Ther. 21:44-54, 2005.
17. Troger, J., Sellemond, S., Kieselbach, G., et al. Inhibitory effect of certain neuropeptides on the proliferation of human retinal pigment epithelial cells. Br. J. Ophthalmol. 87:1403-1408, 2003.
18. Chen, A.Y., and Liu, L.F. DNA topoisomerases: Essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 34:191-218, 1994.
19. Sinha, B.K. Topoisomerase inhibitors. Drugs 49:11-19, 1995.
20. Froelich-Ammon, S.J., and Osheroff, N. Topoisomerase poisons: Harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270:21429-21432, 1995.
21. Fastenberg, D.M., Diddie, K.R., Dorey, K., et al. The role of cellular proliferation in an experimental model of massive periretinal proliferation. Am. J. Ophthalmol. 93:565-572, 1982.
22. Fastenberg, D.M., Diddie, K.R., Sorgente, N., et al. A comparision of different cellular inocula in an evperimental model of massive periretinal proliferation. Am. J. Ophthalmol. 93:559-564, 1982.
23. Lazo, J.S., and Larner, J.M. Individual antineoplastic drugs. In: Brody, T.M., Larner, J., and Minneman, K.P., eds. Human Pharmacology, 3rd ed. St Louis: Mosby, 1998:599-613.
24. Hande, K.R. Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 34:1514-1521, 1998.
25. Meresse, P., Dechaux, E., Monneret, C., et al. Etoposide: Discovery and medicinal chemistry. Curr. Med. Chem. 11:2443-2466, 2004.